Fragmented CKD drugs market to reach $15.8 billion by 2024; Report

22 March 2017

The global chronic kidney disease (CKD) drugs market is largely fragmented, states a research report by Transparency Market Research (TMR).

The top four players, namely France’s Sanofi (Euronext: SAN) and the USA’s Pfizer (NYSE: PFE), Amgen (Nasdaq: AMGN) and AbbVie (NYSE: ABBV), accounted for a share of only 41.4% in this market in 2015. The prominent players in this market are focusing aggressively on mergers, acquisitions, and strategic alliances to expand their product portfolio, which is likely to lead to market consolidation in the next few years, reports the research study.

According to the report's estimates, the global market for chronic kidney disease drugs was worth $11.5 billion in 2015. Proliferating at a 3.60% compound annual growth rate (CAGR) during the period from 2016 to 2024, the overall opportunity in this market is anticipated to increase to $15.8 billion by the end of the forecast period. Hospitals have surfaced as the key end users of chronic kidney disease drugs and are projected to remain so over the next few years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK